← Back to patent-cliff list
Dermatan sulfate
Tier C — Watch / tradeDermatan sulfate
-
Originator
1998
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PT
Brand：Mistral
Indications (approved)：Venous thromboembolism, Thrombosis, Thrombocytopenia
Regional status
US
-
EU
Approved
1998-07-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Dermatan sulfate?
Approved indications include: Venous thromboembolism, Thrombosis, Thrombocytopenia.
When does the Dermatan sulfate patent expire?
No public expiry year is available for Dermatan sulfate yet; this page updates once verified.
How do I get a quote for Dermatan sulfate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27